Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9H8X9

UPID:
ZDH11_HUMAN

ALTERNATIVE NAMES:
Zinc finger DHHC domain-containing protein 11; Zinc finger protein 399

ALTERNATIVE UPACC:
Q9H8X9; Q6UWR9

BACKGROUND:
The enzyme Palmitoyltransferase ZDHHC11, with alternative names Zinc finger DHHC domain-containing protein 11 and Zinc finger protein 399, is pivotal in palmitoylation, affecting protein function and localization. Beyond its enzymatic role, it serves as an adapter in the innate immune response, recruiting IRF3 to STING1, thus promoting type I interferon activation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Palmitoyltransferase ZDHHC11 offers a promising avenue for therapeutic intervention. Its dual role in cellular processes and immune response modulation presents a unique opportunity for the development of novel treatments targeting these pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.